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Objectives. We examined whether long-term nitroglycerin
(NTG) treatment leads to an increase in sensitivity to vasocon-
strictors. To assess a potential role of the renin-angiotensin
system in mediating this phenomenon, we treated patients con-
comitantly with the angiotensin-converting enzyme (ACE) inhib-
itor captopril.
Background. The anti-ischemic efficacy of organic nitrates is
rapidly blunted by the development of nitrate tolerance. The
underlying mechanisms are most likely multifactorial and may
involve increased vasoconstrictor responsiveness.
Methods. Forearm blood flow and vascular resistance were
determined by using strain gauge plethysmography. The short-
term responses to intraarterial angiotensin II (1, 3, 9 and 27
ng/min) and phenylephrine (an alpha-adrenergic agonist drug,
0.03, 0.1, 0.3 and 1 mg/min) were studied in 40 male patients with
stable coronary artery disease. These patients were randomized
into four groups receiving 48 h of treatment with NTG (0.5 mg/kg
body weight per min) or placebo with or without the ACE inhibitor
captopril (25 mg three times daily).
Results. In patients treated with NTG alone, the maximal
reductions in forearm blood flow in response to angiotensin II and
phenylephrine were markedly greater (264 6 3% and 253 6 4%,
respectively) than those in patients receiving placebo (241 6 2%
and 242 6 2%, respectively). Captopril treatment completely
prevented the NTG-induced hypersensitivity to angiotensin II and
phenylephrine (233 6 3% and 235 6 3%, respectively) but had
no significant effect on blood flow responses in patients without
NTG treatment (234 6 2% and 237 6 3%, respectively).
Conclusions. We conclude that continuous administration of
NTG is associated with an increased sensitivity to phenylephrine
and angiotensin II that is prevented by concomitant treatment
with captopril. The prevention of NTG-induced hypersensitivity to
vasoconstrictors by ACE inhibition indicates an involvement of
the renin-angiotensin system in mediating this phenomenon.
(J Am Coll Cardiol 1998;31:83–8)
©1998 by the American College of Cardiology
Nitroglycerin (NTG) remains one of the most useful drugs in
the short-term management of acute ischemic coronary syn-
dromes (for review see [1]). However, the long-term hemody-
namic and anti-ischemic efficacy of organic nitrates is rapidly
attenuated by the development of nitrate tolerance (2,3). The
mechanisms involved in the attenuation of the vasodilator
effects of NTG are probably multifactorial and may include
neurohormonal counterregulatory mechanisms, a desensitiza-
tion of the target enzyme guanylyl cyclase or a decreased NTG
biotransformation (liberation of nitric oxide [NO]) of the
organic nitrate (4,5). Much less attention has been brought to
a potential role of vasoconstrictors in contributing to nitrate
tolerance. Previous experimental studies (6,7) have shown that
long-term treatment with high dose NTG is associated with an
increase in sensitivity to alpha-adrenergic stimuli such as
phenylephrine and epinephrine. Because part of these phe-
nomena were blocked by using alpha1-adrenoreceptor antag-
onists, it was hypothesized (6) that long-term treatment with
NTG causes a specific sensitization of these receptors. Re-
cently, however, we (8) demonstrated in an animal model of
nitrate tolerance that 3 days of continuous treatment with
NTG was associated with enhanced vasoconstrictions not only
to norepinephrine but also to serotonin, angiotensin II and
potassium chloride, suggesting that this phenomenon is not
restricted to a specific upregulation of alpha-adrenoreceptors.
The present study was therefore performed to determine,
whether long-term NTG treatment induces increased sensitiv-
ity to various neurohormonal stimuli in patients with stable
coronary artery disease.
To address a potential involvement of the renin-angiotensin
system in mediating this phenomenon, we treated patients
concomitantly with NTG and the angiotensin-converting en-
zyme (ACE) inhibitor captopril.
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Methods
Study patients. Forty male patients (mean age 57 6 4 years
[range 39 to 72]) with stable coronary artery disease were
studied (Table 1). All patients included in this study were
admitted to the hospital for diagnostic cardiac catheterization.
Subjects with unstable angina, recent myocardial infarction
(within 6 weeks), valvular heart disease, ejection fraction
,35%, insulin-dependent diabetes mellitus, arterial hyperten-
sion .160/90 mm Hg, arterial hypotension (systolic pressure
,110 mm Hg) or a history of nitrate intolerance were ex-
cluded. Cardiovascular medications (beta-adrenergic blocking
agents, calcium channel antagonists, long-acting nitrates) were
withheld for $48 h before participation in the study. All
participants gave written informed consent, and the study
protocol was approved by the Ethical Committee of the
University of Freiburg.
Study protocol. A schematic diagram (Fig. 1) summarizes
the study protocol. Subjects were initially screened by medical
history and physical examination. Measurements of blood
pressure, heart rate and rest forearm blood flow were obtained
(248 h time point). Patients were then recruited in random-
ized fashion to receive either ACE inhibitor treatment with
captopril (25 mg three times daily [t.i.d.]) or no captopril. In
patients allocated to receive ACE inhibitor treatment, the final
captopril dose (25 mg t.i.d.) was titrated over a 2-day period.
On day 1 all patients receiving captopril received 12.5 mg t.i.d.;
on day 2 they received 25 mg t.i.d., a concentration previously
shown (9) to prevent the development of nitrate tolerance in
healthy volunteers. After this 2-day period, all patients were
reevaluated in examinations that included measurement of
blood pressure, heart rate and baseline forearm blood flow (0 h
time point in the protocol, Fig. 1, Table 2). Thereafter, they
were randomized in a single blinded fashion to receive either
treatment with placebo infusion (NaCl 0.9%) or intravenous
(i.v.) treatment with NTG. The chosen NTG concentration was
0.5 mg/kg per min and the infusion period was 48 h. Long-term
NTG infusion was continued throughout the protocol. All
patients were examined for possible adverse reactions and for
recording of supine and standing blood pressure. No patient
exhibited symptomatic postural hypotension or other signifi-
cant side effects. The chosen NTG concentration (0.5 mg/kg
body weight per min) for long-term infusion has been shown
(10,11) to induce tolerance in both the systemic and coronary
circulations within 24 to 48 h. Hemodynamic measurements
were made in every patient between 11 and 12 AM after 48 h of
continuous NTG or placebo infusion and 4 h after oral intake
of the ACE inhibitor.
Hemodynamic measurements. Forearm flow was deter-
mined as recently described (12,13). These studies were per-
formed in a quiet, temperature-controlled room. Under local
anesthesia and sterile conditions, a 20-gauge polyethylene
catheter was inserted into the brachial artery of the nondomi-
nant arm for infusion of drugs. This arm was slightly elevated
above the level of the right atrium, and a mercury-filled Silastic
strain gauge was placed on the widest part of the forearm. The
strain gauge was connected to an electronically calibrated
plethysmograph. A wrist cuff was inflated to suprasystolic
pressures 1 min before and during each measurement to
exclude the hand circulation. A cuff placed on the upper arm
was inflated to 40 mm Hg to occlude venous outflow from the
limb. Flow measurements were recorded for 5 s every 10 s and
Abbreviations and Acronyms
ACE 5 angiotensin-converting enzyme
ANOVA 5 analysis of variance
cGMP 5 cyclic guanosine monophosphate
i.v. 5 intravenous
NO 5 nitric oxide
NTG 5 nitroglycerin
PKC 5 protein kinase C
t.i.d. 5 three times daily
Table 1. Patient Characteristics*
Placebo
(n 5 10)
Placebo 1 Cap
(n 5 10)
48 h of NTG
(n 5 10)
48 h of NTG 1 Cap
(n 5 10)
Age (yr) 58.6 6 4.9 59.4 6 6.3 58.6 6 4.9 60.4 6 5.8
Male/female 10/0 10/0 10/0 10/0
Forearm length (cm) 27 6 1 27.2 6 1.1 27 6 1 26.9 6 0.9
Forearm volume (liters) 1.02 6 0.2 1.1 6 0.12 1.09 6 0.17 1.06 6 0.14
*p 5 NS for all comparisons. Data presented are mean value 6 SEM or number of patients. Cap 5 captopril; NTG 5
nitroglycerin.
Figure 1. Schematic diagram of the protocol design. After initial
hemodynamic evaluation, patients were allocated to receive 48 h of
pretreatment with captopril or no captopril. Thereafter (0-h time
point), patients with or without captopril therapy were randomized in
a single blinded fashion to receive either i.v. infusion of NTG or
placebo (NaCl 0.9%) for 48 h. After 48 h of treatment with NTG or
placebo (48-h time point), forearm studies with intraarterial infusion
of angiotensin II and phenylephrine were performed.
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expressed as ml/min per 100 ml of tissue; the mean flow of
seven consecutive readings was used for analyses.
All subjects rested $30 min after catheter placement to
establish a stable baseline. Basal measurements were then
obtained during intrarterial infusion of 0.9% saline solution at
a rate of 1.66 ml/min. To assess alpha1-adrenoceptor respon-
siveness, phenylephrine was administered at increasing doses
of 0.03, 0.1, 0.3 and 1 mg/min. Angiotensin II was given at doses
of 1, 3, 9 and 27 ng/min. Each dose was infused at a rate of
1.66 ml/min for 5 min, and forearm flow was measured during
the last 2 min of each infusion. A 30-min rest period was
allowed and basal measurements were repeated between the
infusion of the two drugs. Throughout the infusion of vasocon-
strictor agents, the long-term infusion of either NaCl 0.9% or
NTG was continued.
Systolic, diastolic and mean arterial pressures and heart
rate were determined at the contralateral arm with a Dinamap
(845 oscillometric) blood pressure recorder. Forearm vascular
resistance was calculated as the ratio of mean blood pressure
to forearm blood flow. The volume of the forearm, excluding
hand and wrist, was measured by water displacement.
Statistical analysis. All values are reported as mean
value 6 SEM. Group comparisons with respect to baseline
characteristics were done by using one-way analysis of variance
(ANOVA). The influence of NTG and captopril treatment on
the responses to angiotensin II and phenylephrine was assessed
in a 2 3 2 factorial design and analyzed by three-way ANOVA
for repeated measures considering interaction between the two
treatments. If an interactive effect of NTG and captopril
reached statistical significance, the nature of this interaction
was further investigated by applying a two-way ANOVA for
repeated measures to all four treatment groups (placebo,
placebo plus captopril, NTG and NTG plus captopril) without
consideration of the factorial design. Statistical significance
was accepted at a level of alpha 5 5%.
Results
Patient characteristics. In all patients studied, there was
no significant difference between the four treatment groups in
terms of age, blood pressure, heart rate, forearm length or
forearm volume (Tables 1 and 2).
Effects of captopril on systemic and forearm hemodynamic
variables in patients treated with and without captopril.
Changes in systemic hemodynamics and forearm hemody-
namic variables in response to long-term NTG or placebo
treatment are summarized in Table 2. There were no signifi-
cant differences with respect to systemic or forearm hemody-
namic variables between measurements (before NTG or pla-
cebo treatment).
Effects of captopril on vasoconstrictor responses to angio-
tensin II and phenylephrine. Intraarterial infusion of angio-
tensin II and phenylephrine caused a dose-dependent decrease
in forearm arterioles. The reductions in forearm blood flow in
response to angiotensin II and phenylephrine were markedly
greater in patients treated with NTG alone (264 6 3% and
253 6 4%, respectively) than in patients receiving placebo
(241 6 2% and 242 6 2%, respectively) (Fig. 2 and 3).
Concomitant treatment with the ACE inhibitor captopril com-
pletely prevented this hypersensitivity in the NTG-treated
group (233 6 3% vs. 225 6 35%, respectively). Captopril
therapy alone had no significant effect on vascular responses to
either angiotensin II or phenylephrine in the placebo group
(234 6 2% and 237 6 3%, respectively).
Changes in vascular resistance mirrored in a reciprocal
fashion the responses of forearm flow in all four groups (Fig. 2
and 3).
Discussion
To our knowledge, this study provides the first evidence
that long-term treatment with NTG induces hypersensitivity to
Table 2. Effects of 48 Hours of Treatment With NTG or Placebo on Systemic and Forearm
Hemodynamic Variables in Patients With or Without Captopril Treatment*
Placebo
(n 5 10)
Placebo 1 Cap
(n 5 10)
48 h of NTG
(n 5 10)
48 h of NTG 1 Cap
(n 5 10)
Mean arterial pressure (mm Hg)
0 h 92 6 3 92 6 3 92 6 3 94 6 3
48 h 93 6 4 91 6 2 93 6 3 89 6 2
Heart rate (beats/min)
0 h 67 6 7 67 6 11 65 6 6 69 6 10
48 h 69 6 6 66 6 8 71 6 9 75 6 7
Forearm blood flow (ml/min per
100 ml of tissue)
0 h 3.0 6 0.2 3.0 6 0.3 2.9 6 0.3 2.9 6 0.2
48 h 3.1 6 0.1 2.9 6 0.2 2.9 6 0.4 3.0 6 0.2
Forearm vascular resistance (U)
0 h 30.6 6 1.6 31.2 6 1.9 31.0 6 1.1 30.5 6 1.2
48 h 31.1 6 0.9 29.9 6 1.2 29.7 6 1.6 29.9 6 1.1
*p 5 NS for all comparisons. Data presented are mean value 6 SEM. Abbreviations as in Table 1.
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vasoconstrictors in forearm resistance vessels of patients with
stable coronary artery disease. This hypersensitivity was com-
pletely prevented by concomitant treatment with the angioten-
sin I-converting enzyme inhibitor captopril, suggesting that this
phenomenon is mediated by angiotensin II released either
systemically or locally in response to nitrate therapy. It is likely
that the observed increase in sensitivity of the vasculature to
neurohormonal agents contributes to nitrate tolerance by
counteracting vasodilator effects. Further, this enhanced vaso-
constriction may contribute to rebound vasoconstriction and
ischemia, which are frequently encountered on abrupt discon-
tinuation of nitrate therapy (14,15).
Increased vasoconstrictor sensitivity in response to long-
term NTG-treatment. Previous clinical (3,10,16) and experi-
mental studies (17,18) have primarily focused on the concept
that nitrate tolerance is associated with decreased vasodilation
in response to the drug. Much less attention has been devoted
to the possible role of vasoconstrictors in nitrate tolerance.
Previous experimental studies (6,7) have demonstrated that
long-term treatment with high dose NTG was associated with
an increase in sensitivity to alpha-adrenergic stimuli such as
epinephrine and phenylephrine. By treating rats for 4 to 7 days
with NTG (200 mg/kg subcutaneously), Molina et al. (7)
observed that tolerance to NTG was associated with a marked
cross tolerance to endothelium-dependent and -independent
nitrovasodilators and with an increase in sensitivity to norepi-
nephrine. They also observed that norepinephrine had no
effect on cyclic guanosine monophosphate (cGMP) levels in
control vessels, whereas in NTG-tolerant aorta norepinephrine
significantly decreased cGMP levels in tolerant aorta. There-
fore, they concluded that cGMP may play an important
physiologic negative feedback signal in hormone- or autacoid-
induced smooth muscle contraction and that the observed
increase in sensitivity to norepinephrine may be explained by a
desensitization of the guanylyl cyclase and also by the cGMP-
lowering effects of norepinephrine in the setting of nitrate
Figure 2. Mean 6 SEM responses of forearm blood flow (top panel)
and vascular resistance to intraarterial phenylephrine (bottom panel)
in patients after 48 h of placebo infusion (solid circles), after 48 h of
placebo infusion plus ACE inhibitor (captopril) treatment (solid
triangles), after 48 h of NTG infusion (open circles) and after 48 h of
NTG infusion plus ACE inhibitor treatment (open triangles). Contin-
uous treatment with NTG for 48 h markedly increased the sensitivity to
phenylephrine, a phenomenon that was prevented by concomitant
treatment with captopril. The asterisk indicates a significant difference
between the dose-response relation (two-way ANOVA) in patients
treated with NTG alone and that in the other three groups.
Figure 3. Mean 6 SEM responses of forearm blood flow (top) and
vascular resistance (bottom) to intraarterial angiotensin II in patients
after 48 h of placebo infusion (solid circles), after 48 h of placebo
infusion plus ACE inhibitor (captopril) treatment (solid triangles),
after 48 h of NTG infusion (open circles) and after 48 h of NTG
infusion plus ACE inhibitor treatment (open triangles). Continuous
treatment with NTG for 48 h markedly increased the sensitivity to
angiotensin II, a phenomenon that was prevented by concomitant
treatment with captopril. The asterisk indicates a significant difference
between the dose-response relation (two-way ANOVA) in patients
treated with NTG and that in the other three groups.
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tolerance (7). Rydell and Axelsson (6) reported that long-term
treatment of mice with NTG caused a marked increase in
epinephrine toxicity. Because epinephrine toxicity induced by
NTG treatment was inhibited by the alpha1-receptor antago-
nist prazosin, they (6) postulated that this phenomenon is a
rather alpha1-receptor–specific process that may contribute to
withdrawal symptoms and sudden death in industrial workers
exposed to NTG. With the present studies, however, we can
extend these experimental observations by demonstrating that
reductions in forearm blood flow in response to intraarterial
infusions were markedly enhanced in response not only to the
alpha-receptor agonist phenylephrine but also to angiotensin
II in patients pretreated with NTG for 48 h. Therefore, the
increase in sensitivity to two different vasoconstrictors suggests
that this phenomenon is not specific to any one agonist but may
more likely involve an intracellular signaling process shared by
the different receptors activated by these agonists.
The observation of enhanced vasoconstriction to various
agonists is in line with recent experimental studies (8) demon-
strating that in the setting of nitrate tolerance in rabbit aorta,
the sensitivity of the vasculature is increased to vasoconstric-
tors including phenylephrine, serotonin, angiotensin II and
KCl. In vitro, increased vasoconstriction to phenylephrine and
angiotensin II could be blocked by preincubating tolerant
vessels with protein kinase C (PKC) inhibitors such as calphos-
tin C and staurosporin, suggesting an involvement of PKC (an
important second messenger for smooth muscle contraction
[19]) in mediating this phenomenon. Our concept of a PKC-
induced vasoconstrictor hypersensitivity in nitrate tolerance
was recently confirmed by the observation that in vivo treat-
ment of rats with the PKC antagonist N-benzoyl staurosporin
completely prevented the increase in sensitivity to cat-
echolamines and a thromboxane agonist (20).
What mechanisms are responsible for the activation of PKC
in response to long-term NTG treatment? NTG therapy in a
concentration of 0.3 to 0.5 mg/kg per min is associated with a
transient activation of the circulating renin-angiotensin system
and increases in circulating vasopressin levels (21,22). Angio-
tensin II and vasopressin activate PKC (19) and increase the
autocrine (local) production of endothelin-1 in vascular tissue
(23,24), a phenomenon that was recently demonstrated (8) to
occur also in vivo in response to NTG treatment. Autocrine-
produced endothelin-1 within vascular smooth muscle cells
may serve as a “priming” stimulus for PKC, which in turn
mediates the hypersensitivity to angiotensin II and phenyleph-
rine (8). The hypothesis of an involvement of angiotensin II or
endothelin, or both, in mediating NTG-induced hypersensitiv-
ity to vasoconstrictors is further supported by preliminary
experimental observations demonstrating that concomitant
treatment with the angiotensin II receptor blocker losartan
(AT-1 receptor subtype) significantly inhibits tolerance, the
development of a hypersensitivity to vasoconstrictors (25) and
in parallel the expression of endothelin within the vascular
media (Giaid, Montreal, personal communication).
In agreement with this concept, we observed in the present
study that concomitant treatment with the angiotensin I-
converting enzyme inhibitor captopril prevented the develop-
ment of an NTG-induced hypersensitivity to vasoconstrictors.
The ACE is identical with kininase II, an enzyme involved in
the breakdown of the endothelium-dependent vasodilator bra-
dykinin (26). Thus, high local concentrations of bradykinin in
response to ACE inhibition may stimulate release of NO and
prostacyclin by the endothelium, thereby promoting additional
vasodilation (27). It is tempting to speculate that this could
have contributed to the beneficial effect of ACE inhibition on
hypercontractile responses of the vasculature. However, this
possibility is considered less likely, because captopril therapy in
itself had no significant effect on the forearm blood flow
responses to intraarterial angiotensin II and phenylephrine in
patients treated with placebo. It is therefore conceivable that
angiotensin II- or endothelin-1–mediated cellular events ac-
count at least in part for the observed hypersensitivity to
vasoconstrictors in response to long-term NTG treatment.
Pathophysiologic and therapeutic implications. By sum-
marizing results obtained from vessels from nitrate-tolerant
animals it is interesting to note that tolerance is associated with
increased endothelial superoxide production (28), increased
sensitivity to vasoconstrictors secondary to activation of PKC
(8,20) and increased autocrine production of endothelin-1
within the vascular media (8). The present study extends these
observations from animal studies by demonstrating that long-
term NTG treatment induces hypersensitivity to vasoconstric-
tors in patients with stable coronary artery disease. This
phenomenon occurs within 48 h of long-term i.v. NTG therapy
in concentrations (25 mg/12 h) that are commonly used to treat
patients with unstable angina or myocardial infarction. Thus, it
is conceivable that in addition to venous tolerance (which
occurs within 24 h of NTG treatment (29), enhanced propen-
sity of arterioles for vasoconstriction to circulating neurohor-
mones may contribute to the early attenuation of the vasodi-
lator effects of NTG (11) and also to the rebound phenomena
encountered after cessation of long-term NTG therapy (15).
There is experimental evidence (25,31) that tolerance and
enhanced vasoconstriction in the setting of nitrate tolerance
might be beneficially influenced by the use of hydralazine (30),
high dose AT-1 receptor blockade or high dose ACE inhibi-
tion, which might be at least in part attributed to the efficacy of
these drugs to inhibit angiotensin II–induced superoxide pro-
duction or PKC activation in endothelial and smooth muscle
cells.
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